Servaas is Senior Analyst and Co-Manager of the Biotechnology and Oncology strategy at Candriam.
Servaas joined the firm in 2016. Previously, he was a Risk Analyst at AXA Belgium and a Postdoctoral Researcher at Katholieke Universiteit Leuven. He has worked in the financial services industry since 2014.
Servaas earned a Master’s Degree in Chemistry and a Ph.D in Science from Katholieke Universiteit Leuven in Belgium.
Affiliations
Chartered Financial Analyst (CFA)